Mono Pharmacare (NSE:MONOPHARMA) Other Current Liabilities: ₹45 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MONOPHARMA Mono Pharmacare Ltd NSE:MONOPHARMA
9 GF Score
Price ₹7.85
! 6 Warning Signs
View Full Analysis

What is Mono Pharmacare Other Current Liabilities?

Mono Pharmacare NSE:MONOPHARMA +3.29% 9 Other Current Liabilities is ₹45 Mil as of Sep. 2025. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 9/100. The stock has 6 warning signs investors should review.

Mono Pharmacare's other current liabilities for the quarter that ended in Sep. 2025 was ₹45 Mil.

Mono Pharmacare's quarterly other current liabilities increased from Sep. 2024 (₹30 Mil) to Mar. 2025 (₹45 Mil) but then declined from Mar. 2025 (₹45 Mil) to Sep. 2025 (₹45 Mil).

Mono Pharmacare's annual other current liabilities declined from Mar. 2023 (₹15 Mil) to Mar. 2024 (₹10 Mil) but then increased from Mar. 2024 (₹10 Mil) to Mar. 2025 (₹45 Mil).

Mono Pharmacare Other Current Liabilities Related Terms

Mono Pharmacare Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Mono Pharmacare's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mono Pharmacare Other Current Liabilities Chart

Mono Pharmacare Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Other Current Liabilities
1.19 2.92 15.02 10.26 45.30

Mono Pharmacare Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only 17.26 10.26 30.20 45.30 45.02
NSE:MONOPHARMA
9GF Score
Mono Pharmacare Ltd NSE:MONOPHARMA
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mono Pharmacare Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ₹45 Mil mean?
Mono Pharmacare (NSE:MONOPHARMA) has a Other Current Liabilities of ₹45 Mil as of Sep. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Mono Pharmacare.
Is Mono Pharmacare's Other Current Liabilities too high?
Mono Pharmacare's current Other Current Liabilities is ₹45 Mil. Overall, Mono Pharmacare has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Other Current Liabilities compare to competitors?
Mono Pharmacare's Other Current Liabilities of ₹45 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Healthcare Providers & Services company?
A good Other Current Liabilities depends on the Healthcare Providers & Services industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Mono Pharmacare. Mono Pharmacare's current Other Current Liabilities is ₹45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Other Current Liabilities of ₹45 Mil. The current Other Current Liabilities is ₹45 Mil. Mono Pharmacare's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Other Current Liabilities is ₹45 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mono Pharmacare Business Description

Address 1A, Krinkal Apartment, Opposite Mahalaxmi Temple, Paldi, Ahmedabad, GJ, IND, 380007
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
9GF Score

Get the complete analysis for NSE:MONOPHARMA

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹7.85
Price